PTGX

Protagonist Therapeutics (PTGX)

About Protagonist Therapeutics (PTGX)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Details

Daily high

$85.20

Daily low

$80.65

Price at open

$82.83

52 Week High

$96.54

52 Week Low

$33.70

Market cap

5.2B

Dividend yield

0.00%

Volume

609,099

Avg. volume

824,068

P/E ratio

132.44

Protagonist Therapeutics News